Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Jazz Pharmaceuticals Stock a Buy?

TheMotleyFool

0 0

Is Jazz Pharmaceuticals Stock a Buy?Photo, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png

In February, biotech company Jazz Pharmaceuticals (NASDAQ: JAZZ) made some noise when it announced it would acquire GW Pharmaceuticals, a drugmaker specializing in developing cannabidiol (CBD)-derived medicines. The cash-and-stock transaction, which closed in May, was valued at $7.2 billion and represented an almost 50% premium to GW Pharma's market value.

While there are good reasons why Jazz Pharma decided to make this move, acquisitions don't always work as planned. Over the past year, Jazz's stock has outperformed the market and its shares have gotten a bit more expensive, as the graph below shows. With this backdrop in mind, is now a good time to get in on this biotech stock?